Vaccination against herpes zoster became part of the National Vaccine Prevention Plan in 2017 but from this year, thanks to an extraordinary research work, there is the availability of a new vaccine that has recorded important results in terms of effectiveness. And from the 54th national congress of the Italian Society of Hygiene – which is taking place in Lecce – the challenge of making it immediately available on a large scale in all Italian regions starts. “It is a safe, effective and long-lasting vaccine” is the message launched by Roberto Ieraci, director of Uoc Vaccinazioni Internazionale Asl Roma 1. Ieraci also underlines the absolute compatibility of the vaccine with the co-administration strategy: “This vaccine can be co-administered in peace with all inactivated vaccines, including the flu, ”explains the expert.
Shingles, also known as shingles, has crippling effects in the lives of patients who are affected by it. The complications are significant: post herpetic neuralgia often causes terrible pain and there is currently no satisfactory therapy. It is clear that this pathology can have more serious consequences in frail patients, from those with coronary diseases to those with cancer. The new vaccine has a more than satisfactory response in terms of coverage, which shows no signs of diminishing over time. However, the results on the vaccination front are less satisfactory, which is now very far from the 50% target set by the vaccination plan.
“We, in the Lazio region, started from the point of view of the flu vaccination and – adds Ieraci – we are working to ensure that this new vaccine is also available especially for immunosuppressed and immunosuppressed subjects who are in great need of it. And here I put the large number of cancer patients and patients being treated with biological and immunosuppressive drugs, which are many and need to have adequate and specific protection against a fearful disease such as Herpes Zoster “.
#Ieraci #vaccine #Herpes #Zoster #effective #fragile #immunized